Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02927067 · ClinicalTrials.gov registry record · Phase 3
A Study of Maribavir Compared to Valganciclovir to Treat Cytomegalovirus Infections in People Who Have Received Stem Cell Transplants
A Phase 3 study, sponsored by Shire.
- Completed
- Registry status
- Phase 3
- Development phase
- 553
- Enrollment target
NCT02927067 is a Phase 3 study that has completed, run by Shire. The registered enrollment target is 553 participants.
The verdict
NCT02927067, a Phase 3 study, has completed, sponsored by Shire.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 553 participants
- Enrollment target
Study Summary
This study is about treatment options for cytomegalovirus infections in people who have received stem cell transplants. The main aim of the study is to check if the cytomegalovirus infection can no longer be detected after treatment with marivabir or valganciclovir. Participants will take 2 tablets of marivabir or valganciclovir and 2 tablets of placebo twice a day for 8 weeks. A placebo will look like marivabir or valganciclovir but will not have any medicine in it. After treatment, each participant will be followed up for up to 12 weeks. Participants will visit their study clinic up to 18 times during the study.
Interventions
- OTHER Placebo
- DRUG Valganciclovir
- DRUG Maribavir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 553 participants |
| Start Date | 2017-04-14 |
| Est. Completion | 2022-07-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02927067
The ClinicalTrials.gov registry entry for NCT02927067 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 553 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Shire, which has 245 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02927067 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02927067 about?
NCT02927067 is a clinical study titled "A Study of Maribavir Compared to Valganciclovir to Treat Cytomegalovirus Infections in People Who Have Received Stem Cell Transplants". This study is about treatment options for cytomegalovirus infections in people who have received stem cell transplants. The main aim of the study is to check if the cytomegalovirus infection can no longer be detected after treatment with marivabir or valganciclovir. Participants will take 2 tablets...
What is the current status of trial NCT02927067?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 553 participants. The study started on 2017-04-14. Estimated completion is 2022-07-01.
What interventions are being tested in trial NCT02927067?
The interventions under investigation include: Placebo (OTHER), Valganciclovir (DRUG), Maribavir (DRUG).
Who is sponsoring clinical trial NCT02927067?
This trial is sponsored by Shire, which has 245 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.